BXCL501 for Agitation in Schizophrenia

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 9, 2020

Primary Completion Date

May 26, 2023

Study Completion Date

May 26, 2023

Conditions

SchizophreniaSchizoaffective Disorder

Interventions

DRUG

Dexmedetomidine Hydrochloride

DRUG

Placebos

Placebo

Trial Locations (1)

Connecticut Mental Health Center, New Haven

All Listed Sponsors

lead

Yale University

OTHER

NCT03708315 - BXCL501 for Agitation in Schizophrenia | Biotech Hunter | Biotech Hunter